Compare GEVO & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GEVO | PRQR |
|---|---|---|
| Founded | 2005 | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 568.2M | 167.5M |
| IPO Year | 2010 | 2014 |
| Metric | GEVO | PRQR |
|---|---|---|
| Price | $2.37 | $1.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $6.42 | ★ $7.67 |
| AVG Volume (30 Days) | ★ 3.7M | 273.3K |
| Earning Date | 03-05-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.82 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $711,000.00 | N/A |
| Revenue This Year | $19.44 | $18.88 |
| Revenue Next Year | $5.59 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.92 | $1.08 |
| 52 Week High | $2.95 | $3.10 |
| Indicator | GEVO | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 63.77 | 40.14 |
| Support Level | $2.26 | $1.33 |
| Resistance Level | $2.46 | $1.58 |
| Average True Range (ATR) | 0.15 | 0.11 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 75.97 | 5.56 |
Gevo Inc is a growth-oriented company that focuses on hard to decarbonize market sectors such as jet fuel, certain specialty fuels, on-road fuels, chemicals and materials, and certain products for the food chain such as protein and feeds made as co-products from its processes. It produces and sells competitively priced, renewable, drop-in products for these sectors, and generate carbon abatement value through its plant design and business systems. It owns and operates an ethanol plant with an adjacent CCS facility, Class VI carbon-storage well, and others. The group is currently developing the world's first large-scale ATJ facility to be co-located at the North Dakota site.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.